Cell and Gene Therapy Global Market Report 2022: By Product, By Application, By End-User

Cell and Gene Therapy Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global cell & gene therapy market.

This report focuses on cell & gene therapy market which is experiencing strong growth. The report gives a guide to the cell & gene therapy market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
Create regional and country strategies on the basis of local data and analysis
Identify growth segments for investment
Outperform competitors using forecast data and the drivers and trends shaping the market
Understand customers based on the latest market research findings
Benchmark performance against key competitors
Utilize the relationships between key data sets for superior strategizing
Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the cell & gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cell and Gene Therapy market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cell & gene therapy market, and compares it with other markets.

The market characteristics section of the report defines and explains the market
The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
Market segmentations break down market into sub markets
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
The cell & gene therapy market section of the report gives context. It compares the cell & gene therapy market with other segments of the cell & gene therapy market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cell & gene therapy indicators comparison

Scope

Markets Covered:

1) By Product: Cell Therapy; Gene Therapy
2) By Application: Oncology; Dermatology; Musculoskeletal; Others
3) By End User: Hospitals; Ambulatory Surgical Centers; Cancer Care Centers; Wound Care Centers; Others

Companies Mentioned: Gilead Sciences; Bristol-Myers Squibb; Novartis AG; Amgen; Merck

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Frequently Asked Questions about the Global Cell and Gene Therapy Market

What is the estimated value of the Global Cell and Gene Therapy Market?

The Global Cell and Gene Therapy Market was estimated to be valued at $8.6 billion in 2022.

What is the growth rate of the Global Cell and Gene Therapy Market?

The growth rate of the Global Cell and Gene Therapy Market is 25.6%, with an estimated value of $21.3 billion by 2026.

What is the forecasted size of the Global Cell and Gene Therapy Market?

The Global Cell and Gene Therapy Market is estimated to be worth $21.3 billion by 2026.

Who are the key companies in the Global Cell and Gene Therapy Market?

Key companies in the Global Cell and Gene Therapy Market include Gilead Sciences, Bristol, Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon and Bluebird Bio.

1. Executive Summary2. Cell and Gene Therapy Market Characteristics3. Cell and Gene Therapy Market Trends And Strategies4. Impact Of COVID-19 On Cell and Gene Therapy

5. Cell and Gene Therapy Market Size And Growth

5.1. Global Cell and Gene Therapy Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Cell and Gene Therapy Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Cell and Gene Therapy Market Segmentation

6.1. Global Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Cell Therapy
Gene Therapy

6.2. Global Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Oncology
Dermatology
Musculoskeletal
Others

6.3. Global Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Hospitals
Ambulatory Surgical Centers
Cancer Care Centers
Wound Care Centers
Others

7. Cell and Gene Therapy Market Regional And Country Analysis

7.1. Global Cell and Gene Therapy Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Cell and Gene Therapy Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Cell and Gene Therapy Market

8.1. Asia-Pacific Cell and Gene Therapy Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Cell and Gene Therapy Market

9.1. China Cell and Gene Therapy Market Overview
9.2. China Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Cell and Gene Therapy Market

10.1. India Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Cell and Gene Therapy Market

11.1. Japan Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Cell and Gene Therapy Market

12.1. Australia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Cell and Gene Therapy Market

13.1. Indonesia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Cell and Gene Therapy Market

14.1. South Korea Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Cell and Gene Therapy Market

15.1. Western Europe Cell and Gene Therapy Market Overview
15.2. Western Europe Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Cell and Gene Therapy Market

16.1. UK Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Cell and Gene Therapy Market

17.1. Germany Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Cell and Gene Therapy Market

18.4. France Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Cell and Gene Therapy Market

19.1. Eastern Europe Cell and Gene Therapy Market Overview
19.2. Eastern Europe Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Cell and Gene Therapy Market

20.1. Russia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Cell and Gene Therapy Market

21.1. North America Cell and Gene Therapy Market Overview
21.2. North America Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Cell and Gene Therapy Market

22.1. USA Cell and Gene Therapy Market Overview
22.2. USA Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Cell and Gene Therapy Market

23.1. South America Cell and Gene Therapy Market Overview
23.2. South America Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Cell and Gene Therapy Market

24.1. Brazil Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Cell and Gene Therapy Market

25.1. Middle East Cell and Gene Therapy Market Overview
25.2. Middle East Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Cell and Gene Therapy Market

26.1. Africa Cell and Gene Therapy Market Overview
26.2. Africa Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Cell and Gene Therapy Market Competitive Landscape And Company Profiles

27.1. Cell and Gene Therapy Market Competitive Landscape
27.2. Cell and Gene Therapy Market Company Profiles
27.2.1. Gilead Sciences
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bristol-Myers Squibb
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Novartis AG
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Amgen
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Merck
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Cell and Gene Therapy Pipeline Analysis29. Key Mergers And Acquisitions In The Cell and Gene Therapy Market30. Cell and Gene Therapy Market Future Outlook and Potential Analysis

31. Appendix

31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.

The global cell and gene therapy market is expected to grow from $6.58 billion in 2021 to $8.57 billion in 2022 at a compound annual growth rate (CAGR) of 30.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $21.33 billion in 2026 at a CAGR of 25.6%.

The cell and gene therapy market consist of sales of cell and gene therapies by entities (organizations, sole traders and partnerships) that develop cell and gene therapies. Cell therapy refers to the transfer of intact, live cells that are originated from autologous or allogenic sources and gene therapy refers to the introduction, removal, or change in the genome for treating diseases. The market consists of revenue generated by the companies developing cell and gene therapy products by the sales of these products.

The main types of products in cell and gene therapy are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to heal disease by repairing or reconstructing damaged genetic material. The different applications include oncology, dermatology, musculoskeletal, others and involves various sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market. After recognizing the potential of the CGT market, 16 out of the 20 largest biopharma companies by revenue, added CGT products to their portfolio. For instance, Merck invested $109 million in viral vector and gene therapy manufacturing in April 2020. Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. Steady investment and consolidation in CGT production capacity led to an increase in production capacity and also contributed to the growth of the market.

Limited reimbursements preventing patients from receiving treatments are expected to limit the growth of cell and gene therapy (CGT market. In 2019, Trinity Life Sciences, a life sciences solution provider, researched national and large regional commercial health insurance plans in the US. It found that the confluence of increasing price, patient volume and number of CGTs on the market is likely to change the reimbursement model for CGTs and impact payer budgets by 5-10%. Payers realize that financing needs to be generated for cost management due to the uncertainty surrounding reimbursement of ancillary costs. Limited reimbursements and uncertain insurance plans are preventing patients from receiving high-cost CGT, which is expected to limit market growth.

Chimeric antigen receptor (CAR) T-cell therapy is shaping the cell and gene therapy (CGT) market. (CAR) T-cell therapy is a combination of cell and gene therapy in which T cells are collected from the patient’s blood and are genetically engineered to produce modified receptors at their surface, known as chimeric antigen receptors (CARs). These modified T cells with special structures (receptors) are reinfused into the patient. Then, the modified receptors of T cell help in targeting the surface antigen of the cancer cell that ultimately results in the killing of tumor cells in patients. In 2020, the US-FDA approved Bristol-Myers Squibb's two CAR-T cell therapies to treat lymphoma and multiple myeloma and is set to be launched. Currently, FDA approved CAR-T cell therapy treatments like Tisagenlecleucel for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in children and Axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

In December 2019, Roche, a Swiss multinational healthcare company, acquired Spark Therapeutics for $4.3 billion. The acquisition supports the commitment of Roche to bring transformational therapies and innovative approaches to people with serious illnesses. Spark Therapeutics will continue to work within the Roche Group as an independent company. Spark Therapeutics, headquartered in Philadelphia, is a fully integrated commercial company involved in the discovery, production, and distribution of gene therapies for genetic disorders including blindness, hemophilia, lysosomal storage, and neurodegenerative diseases.

The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.